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INTERODUCTION  
The oral drug delivery system has overcome a no. of 
limitation such as degradation of drug by enzyme, 
irritation of gastro intestinal mucosa and first pass 
metabolism effect. Also due to the pain on 
administration associated with parental route.
1,2
 Due to 
the above resion the transdermal route is highly prefer 
by the patient hence research the ethosome carrier 
moiety for the transdermal drug delivery system. The 
ethosome are used for delivery of drug by transdermal 
route, this route is most important route of drug 
administration. Ethosome are interesting and innovative 
drug delivery system that have large field in 
pharmaceutical technology and drug delivery in resent 
year. The ethosome are used for those drugs that have 
lower penetration to the membrane of skin. These are 
ethonlic liposomes. Ethosome are lipid vesicle 
containing phospholipids alcohol (ethonal and isopropyl 
alcohol) in high concentration and water.
 3 
 It is a soft 
vesicle. The size range of ethosome may vary from tens 
nanometers to microns ethosomes permeate through the 
skin layers more rapidly and possess significantly higher 
transdermal flux. 
3, 4, 5, 6 
 The ethosome is used for 
delivery of drug by transdermal route. This route is most 
important route of drug administration. The ethosome is 
transport the active drug through the stratum corneum 
layer of skin in comparison to the conventional 
liposome.
 3, 7
   For the trance dermal drug delivery the 
stratum corneum layer is main barrier for permeation , 
for this aspect design a carrier to be applied topically 
both for topically and systemic drug administration. The 
combination of phospholipids and higher concentration 
of ethanol in vesicular formulation is responsible for the 
systemic effect and for the deeper distribution and 
penetration in the skin lipid bilayers. Ethosome can 
entrap drug molecule with various physiochemical 
characteristics i.e. of hydro phallic and lipophilic or 
amphiphilic.
 (3, 8, 9) 
Liposome, noisome, transferosome 
and ethosome also have been reported to enhance 
permeability of drug through the stratum corneum 
barrier. Permeation enhancer increases the permeability 
of the skin, so that the drug can be cross through the 
skin.
 3, 10, 11 
 
 
ABSTRACT  
Transdermal drug delivery system was first introduced more than 20 years ago. Transdermal drug delivery system is a type 
of convenient drug delivery system where drug goes to the systemic circulation through the protective barrier i.e. Skin is the 
main target of topical and transdermal preparations. Major aim of transdermal drug delivery system is to cross the stratum 
corneum. Various methods have been tried to increase the permeation rate of drugs temporarily. Vesicular system is one of 
the most controversial methods for transdermal delivery of active substances in that ethosome are the ethanolic 
phospholipids vesicles which are used mainly for transdermal delivery of drugs. Ethosomes are soft, malleable vesicles 
tailored for enhanced delivery of active agents. Ethosomes have higher penetration rate through the skin. The increased 
permeation of ethosomes is probably due to its ethanolic content. Ethanol increases the cell membrane lipid fluidity which 
results in increased skin penetrability of the ethosomes. These ethosomes permeates inside the skin and fuse with cell 
membrane lipids and release the drug. Hot and cold methods are used for formulation of ethosomes. Evaluation parameters 
include size, shape, drug content, zeta potential etc. Ethosomes have been successfully evaluated for the delivery of many 
drugs for e.g. Cyclosporine A, insulin, salbutamol, trihexyphenidil, etc. Ethosomes provides a number of important benefits 
including improving the drug’s efficacy, enhancing patient compliance and comfort and reducing the total cost of treatment. 
Ethosomes can be important drug delivery tool in the future. 
Keywords: Ethosomes, Transdermal, Vesicular carriers, Ethanol, Phospholipid. 
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Figure 1: Microscopic view of Ethosome vesicle 
12
            Figure 2: Structure of ethosome vesicle 
13
 
 
NEED FOR TRANSDERMAL DRUG DELIVERY- 
Despite the challenges, Transdermal delivery (TDD) 
offers several unique advantages including relatively 
large and readily accessible surface area for absorption, 
ease of application and termination of therapy.  Further, 
evolution of better technologies for delivering drug 
molecules, safe penetration enhancers and the use of 
vesicular carriers have rejuvenated the interest for 
designing TDD system for drugs that were thought to be 
unfit for trans dermal delivery. 
ADVANTAGE OF ETHOSOMAL DRUG 
DELIVERY- 
14, 15, 16, 17
 
 Enhanced permeation of drug through skin for 
transdermal drug delivery. 
 It contains non-toxic row material in formulation. 
 Ethosome composition is safe and the components 
are approved for pharmaceutical and cosmetic use. 
 Delivery of lunge molecules (peptides protein 
molecules) is possible. 
 Simple method for drug delivery in comparison to 
iontophoresis and phonophorresis and other 
complication method. 
 The ethosome system is passive non-invasive and is 
available for immediate commercialization. 
 High patient compliance the ethosomal drug is 
administrated in semisolid form (gel or cream) 
hence producing high patient compliance. 
 Ethosomal drug delivery system can be applied 
widely in pharmaceutical vet nary cosmetic field. 
DISADVANTAGE OF ETHOSOME DRUG 
DELIVEY- 
15, 18, 19 
 Drugs that require high blood levels cannot be 
administered – limited only to potent molecules, 
those requiring a daily dose of 10mg or less. 
  Ethosomal administration is not a means to achieve 
rapid bolus type drug input, rather it is usually 
designed to offer slow, sustained drug delivery. 
 Adequate solubility of the drug in both lipophilic 
and aqueous environments to reach dermal 
microcirculation and gain access to the systemic 
circulation. 
 The molecular size of the drug should be reasonable 
that it should be absorbed percutaneously. 
 Adhesive may not adhere well to all types of skin. 
Uncomfortable to wear. 
  May not be economical. Poor yield. 
 Skin irritation or dermatitis due to excipients and 
enhancers of drug delivery systems. 
  In case if shell locking is ineffective then the 
ethosomes may coalescence and fall apart on 
transfer into water. 
  Loss of product during transfer from organic to 
water media. 
  The main advantage of ethosomes over liposomes 
is the increased permeation of the drug. 
COMPOSITION OF ETHOSOME
17, 20
 
Ethosome are vesicular carrier composed of 
hydroalcohalic orhydrolglycolic phospholipids, in which 
the concentration of water and alcohol is high. The high 
concentration of ethanol makes the ethosome unique. 
The rang of alcohol in final product is -20-30%. The 
ethosome is contain phaspholipid with various chemical 
structure  like phasphotidyl choline, hydrogenated 
phasphotidyl choline phasphatic acid and phasphotidyl 
glycerol, phasphatidyl inositol, alcohol, water and 
propylenrglycol. The drug delivery can be change by 
chainging the ratio of alcohol:water or alcohol-
polyol:water.Some preferred phaspholipid are 
soyaphaspholipids such as phaspholipon90 (PL-90), it is 
usually employed in range of 0.5-10% w/w cholesterol 
at connected rangimg b/w 0.1/1% can also be added  to 
the preparation. 
EXAMPLE- Alcohol like ethanol and isopropyl alcohol 
and glycols like propylene glycol transcutol are 
generally used. Some time non-ionic surfactant is used 
with phospholipids preparation and cationic lipid like 
coca-amide POE alkyl amine, dodecylamine, cetrimide 
etc are generally used. The concentration of the non-
aqueous phase (alcohol and glycol) may long b/w 22-
70%.
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Table 1: Defferent Additive Employed in Formulation of Ethosome 
CLASS EXAMPLE USE 
Phospholipids Soya phosphatidyl choline 
Egg phosphatidyl choline 
Dipalmityl phosphatidyl choline 
Distearyl phosphatidyl choline 
Vesicles forming component 
 
Polyglycol Propylene glycol 
Transcutol RTM 
As a skin penetration enhancer 
 
Alcohol Ethanol 
Isopropyl alcohol 
For providing the softness for vesicle membrane 
As a penetration enhancer 
Cholesterol Cholesterol For providing the stability to vesicle membrane 
Dye Rhodamine-123 
 Rhodamine red 
Fluorescene Isothiocynate (FITC) 
6- Carboxy fluorescence 
For characterization study 
Vehicle Carbopol Ð934 As a gel former 
 
SKIN-
21
 
The skin is the largest organ of the body and has surface 
area about 1.5-2cm
2
 in adult. There are 2 important 
layer- a. Epidermis b. Dermis 
The epidermis is most superficial layer of the skin and is 
composed of stratified keratinized squamous epithelium. 
The epidermis is composed of 4-5 layers depending on 
the region of skin being considered. The layers are- 
   a) - cornified layer (stratum corneum) 
  b) - translucent layer (stratum granulosm) 
  c) - spinous layer (stratum spinosm) 
  d) - germinal layer (stratum basale) 
                    
 
Figure 3: Structure of Skin 
22
  
 
a) Stratum corneum –it is composed of 10-30 layers of 
polyhedral anucleated corneocytes, with the palms and 
soles having the most layers. Corneocytes are 
surrounded by a protein envelope, filled with water-
retaining keratin proteins, attached through 
corneodesmosomes and surrounded in the extracellular 
space by stacked layer of lipid. The stratum corneum 
layer plays an important role in the barrier function of 
topical/ transdermal drug delivery. Human skin has 
selective permeability for drug, lipophilic drug can pass 
through the skin but the drug which are hydrophilic in 
nature cannot pass through skin.Water soluble drug 
show either very less or no permeation. To improve the 
permeation of drug through the skin various 
mechanisms have been investigated, including use of 
chemical or physical enhancer such as iontophoresis or 
sonophoresis. Liposomes, niosomes, transferosomes and 
ethosome are also enhancing the permeability of drug 
through stratum corneum. Permeability enhancer 
increase the permeability of the skin so that the drug can 
cross the through the skin easily. Ethosomes can 
enhance permeation through the stratum corneum 
barrier. 
(3, 23, 24) 
 The thickness of stratum corneum layer 
is 10 micro grams and it consists of 10-25 rows of dead 
carneocytes embedded in a lipid matrix. The 
heterogeneous structure of the stratum corneum is 
composed of approximately 75-80% protein, 5-15% 
lipid, 5-10% unidened on a drug ewight basis. 
25
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Figure 4: Cross section of Skin 
26
 
 
 
MECHANISM OF DRUG PENETRATION- 
It is the pass through that the first pass part of the 
mechanism is due to the ethanol effect where by 
interaction of the ethanol into intracellular lipid 
increasing lipid fluidity and decreasing the density of 
lipid multilayer. 
This is followed by the ethosome effect, that includes 
inter lipid penetration and permeation by the opening of 
new pathways due to the fusion of ethosome with skin 
lipid. 
                          
 
 
Figure 5: Release of drug from ethosome in deep layer of the skin 
(29)
 
           DRUG APPLIED TO THE SKIN SURFACE 
FAIL TO PARTITION OUT OF 
CARRIR (without ethosome) 
DRUG PARTITION OUT OF CARRIR IN TO 
SC (with ethosome) 
DRUG METABOLISM     NOT METABOLIED 
          DERMIS 
SYSTEMIC ABSORPTION 
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THE DRUG ABSOPTION OCCURS IN 
FOLLOWING TWO PHASE- 
27, 28
 
a) - Ethanol effect 
b) - Ethosome effect 
 
a) - ETHANOL EFFECT- 
Ethanol acts as a penetration enhancer through the skin. 
The mechanism of penetration enhancing effect is well 
known. Ethanol penetrates into intracellular lipid sand 
increase the fluidity of cell membrane lipid and decrease 
the density of lipid multilayer of cell membrane. 
ETHANOL: AS PENETRATION ENHANCER-  
Substances that reversibly reduce the barrier resistance 
of the stratum corneum are known as chemical 
penetration enhancers. 20 Ethanol is one of the most 
commonly used permeation enhancers. A number of 
mechanisms have been proposed for permeation en-
hancing action of ethanol. As a solvent, ethanol can be 
included in the formulation to enhance the solubility of 
the drug. This is particularly important for poorly so-
luble permeants, as they are prone to depletion in the 
donor vehicle. Ethanol is a relatively volatile solvent 
and will rapidly evaporate at skin tem-perature. Ethanol 
loss from a formulation may lead to the drug becoming 
supersaturated, which influ-ence drug will flux across 
the membrane.
27, 30, 31 
b) – ETHOSOMES EFFECT- 
 
METHOD OF PREPRATION OF ETHOSOME 
Ethosomal formulation may be prepared by hot or cold 
or injection method or optimized method. 
These methods are very simple and convenient and do 
not involve any sophisticated instrument or complicated 
process and easy to scale up at industrial level. 
 
A) - COLD METHOD- 
 
 
 
 
 
 
 
 
 
Take the, phospholipids, drug and other lipid materials 
Dissolved in ethanol in a covered vessel at room temperature 
by vigorous stirring with the use of mixer 
Propylene glycol or other polyol is added during stirring and 
mixture is heated to 300C in water bath. 
  
Pre heated water 300C is added to the mixture, which is then 
stirred for 5 min in a covered vessel. 
 
The vesicle size of ethosomal formulation can be decreased to 
desire extend using sonication or extrusion method. 
The formulation is stored under refrigeration 32, 34 
ETHOSOME 
ETHOSOME COUSE SKIN DISRUPTION 
INCREASE LIPID FLUIDITY 
MORE PENETRATION THROUGH SKIN 
ETHOSOME PENETRATE INSIDE 
FUSE WITH LIPID 
RELESE DRUG INTO DEEP SKIN LAYER 32, 33 
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B) - HOT METHOD 
              
 
C) - INJECTION METHOD 
 
 
D) - OPTIMIZATION METHOD- 
 
 
 
 
 
Take the phaspholipid90 dissolve in ratio of chloroform: methanol 
(3:1) 
Remove the organic solvent from rotator flask evaporator above the 
lipid transition temperature 550C at 600 rpm 
Further remove the organic solvent by maintaining temperature for 30 
min 
Thin film formed and hydrates the film with hydroethanolic mixture 
(1% w/v) at 60 rpm for 1 hour 
Sonication in 3 cycle of 5 min with 5 min rest b/w the cycle Store the 
formulation at 40C in the container.37, 38 
 
 
 
In this method take phospholipids and drug dissolve in 
ethanol and propylene glycol solution in closed vessel 
Heat the mixture to 300C in water bath 
Add slowly-slowly distilled water in a fine stream and 
mixing at700 rpm in closed vessel for 5 min at 300C 
temperature 
Preparation store at 40C, sonication in 3 cycles of 5 min 
with 5 min rest b/w the cycle (36) 
Store the formulation at 40C in the container 15, 37 
In a separate vessel ethanol and propylene glycol are mixed and heated to 400C. Once both mixtures 
reach 400C, the organic phase is added to the aqueous one. 
 
The drug is dissolved in water or ethanol 
The vesicle size of ethosomal formulation can be decreased to the desire extent using probe sonication or 
extrusion method. 32, 34, 35 
 
In these method phospholipids is dispersed in water by heating in a water bath at 400C until a colloidal 
solution is obtained. 
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VARIOUS METHOD OF CHARECTERIZATION 
OF ETHOSOME- 
1. Optical Microscope Observation- 
The ethosomal dispersion is spread on the glass slide 
with the help of glass rod. Prepare the multilamella 
vesicles were detected by examining the ethosomal 
suspension using an optical microscope with the 
magnification power of 100 X. 
27, 39, 40
 
2. Vesicle size and zeta potential- 
Particle size of the ethosomes can be detected by 
dynamic light scattering (DLS) and photon correlation 
spectroscopy (PCS). Zeta potential of the ethosome 
suspension can be measured by Zeta meter
. 27, 41
 
 
3. Transition temperature- 
The transition temperature of the vesicular lipid systems 
can be measured by using differential scanning 
calorimetric.
 27, 42 
4. Visualization- 
Visualization of ethosomes can be done by using 
instrument transmission electron microscopy (TEM) and 
by scanning electron microscopy (SEM). Visualization 
of an ethosomal formulation by the electron microscopy 
reveals exhibited vesicular structure 300-400 nm in 
diameter.
 5, 43 
5. Scanning electron microscopy (SEM)- 
The different type of lipid affects the surface 
morphology or shape of the particles. Solid lipid 
microparticles are deposits on metallic surface then it 
placed in liquid nitrogen and dried under vacuum. The 
microparticles are coated uniformly with gold by freeze-
dried. The morphology and surface properties of 
ethosome formulation can be measured by a scanning 
electron microscope. 
6. Drug content- 
Drug substance or content of the ethosomes can be 
determined by using UV spectrophotometer. This can 
also be quantified by a modified high performance liquid 
chromatographic method. 
7. Stability studies- 
The stability of vesicles can be determined by assessing 
the size and structure of the vesicles over time. It means 
size is measured by DLS and a structural change is 
observed by TEM
. 27, 44 
8. Entrapment Efficiency- 
The entrapment efficiency of drug by ethosomes can be 
measured by the ultra centrifugation 
Technique. 
5, 45
 
8.  Surface tension measurement- 
The surface tension activity of drug in aqueous solution 
can be measured by the ring method in a Du Nouy ring 
tensiometer.
 5, 46
 
9. Skin permeation studies- 
The ability of the ethosomal preparation to penetrate the 
skin layers can be measured by confocal laser scanning 
microscopy (CLSM). 
EVALUATION OF ETHOSOME- 
1. Filter Membrane: Vesicle Interaction Study by 
Scanning Electron Microscopy- Take vesicle 
suspension (0.2 mL) and take a filter membrane having a 
pore size of 50 nm. The formulation is applied on the 
filter membrane and placing it in diffusion cells. The 
upper side of the filter membrane was exposed to the air, 
and the lower side of filter membrane is contact with 
phosphate buffer solution, (having pH 6.5). The filter 
membranes removed after 1 hour and were prepared for 
SEM studies by fixation at the 4°C in Karnovsky’s 
fixative overnight followed by dehydration with graded 
ethanol solutions (30%, 50%, 70%, 90%, 95%, and 
100% v/v in water). Finally, filter membranes was 
coated with gold and examined in SEM.
 47, 48
 
2. Skin Permeation Studies- 
The hair of test animals (rats) is remove or carefully 
trimmed short (<2 mm) with the help of scissors, and the 
abdominal skin is removed from the connective tissue 
with the help of scalpel. The skin is placed on aluminum 
foil, and the dermal side of the skin was gently teased 
off for any adhering fat. The standard permeation area of 
the diffusion cell and receptor cell volume is 1.0 cm
2
 and 
10 ml, respectively. The temperature is maintained at 
32°C+- 1°C. The receptor compartment contained 
phosphate buffer solution (10 ml of pH 6.5). Ethosomal 
formulation (1.0 ml) was applied to the epidermal 
surface of skin. Samples (0.5 ml) were withdrawn 
through the sampling port of the diffusion cell by the 
pippet at 1, 2, 4, 8, 12, 16, 20 & 24 hour time intervals 
and analyzed by high performance liquid 
chromatography assay
. 47
 
3. Vesicle-Skin Interaction Study by TEM and SEM- 
Take the animal and cut the ultra thin sections like (Ultra 
cut, Vienna, and Austria), collect the section to coated 
grids and analyzed by transmission electron microscope. 
For SEM analysis, take the sections of skin and 
dehydrated and mounted on stubs using an adhesive tape 
and coated with gold palladium with the help of fine 
coat ion sputter coater. The sections were analyzed 
under scanning electron microscope.
 47, 48 
4. Vesicle-Skin Interaction Study by Fluorescence 
Microscopy- 
Fluorescence microscopy was carried according to the 
protocol used for TEM and SEM study. 5-μm thick skin 
sections were cut using microtome and examined under 
a fluorescence micro Cytotoxicity Assay MT-2 cells (T-
lymphoid cell lines) were propagated in Dulbecco's 
modified Eagle medium containing 10% fetal calf 
serum, 100 U/ml penicillin, 100 mg/Ml streptomycin, 
and 2 mmol/L L glutamine at 37°C under a 5% CO2 
atmosphere. Cytotoxicity was expressed as the cytotoxic 
dose 50 (CD50) that induced a 50% reduction of 
absorbance at 540 nm.
 47, 49
 
5. Drug Uptake Studies- 
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The uptake of drug into MT-2(T-lymphoid cell lines) 
cells was incubated with 100 μl of the drug solution in 
phosphate buffer saline solution (pH 7.4), Ethosomal 
formulation, or marketed formulation, and then drug 
uptake was determined by analyzing the drug content by 
HPLC assay.
47, 50, 51 
6. HPLC Assay- 
The drug bind with our receptor, and the amount of drug 
permeated in the receptor compartment in the vitro skin 
permeation experiments and in MT-2 cell was 
determined by HPLC. In the HPLC assay using 
methanol: distilled-water : acetonitrile (70:20:10 
vol/vol). This mixture is a mobile phase delivered at 1 
ml/min by LC 10-AT pump. A twenty-micro liter 
injection was eluted in column at room temperature. The 
column Eluent (solution) was examined at 271 nm using 
SPDM10A VP diode array UV detector. The coefficient 
of variance for standard curve ranged from 1.0% to 
2.3%, and the squared correlation coefficient was 
0.9968.
 47, 52, 53 
7. Statistical Analysis- 
Statistical significance of all the data generated was 
tested by employing ANOVA followed by studentized 
range test. A confidence limit of P < .05 was fixed for 
interpretation of the results using the software PRISM. 
47, 54 
APPLICATION OF ETHOSOME AS A CARRIER 
SYSTEM- 
Various methods employing ethosomal formulation have 
shown better skin permeability of drugs. The uses of 
ethosomes as carrier system for transdermal/topical drug 
delivery are given below. 
1. Pilosebaceous targeting- 
Pilosebaceous units have been use for targeted drug 
therapy, and the targeted treatment of follicle related 
disorders such as acne or alopecia. Ethosomal 
formulation of minoxidil is a lipid soluble drug used for 
the baldness accumulates into nude mice skin two to 
seven folds higher and thus can be use for pilosebaceous 
targeting for better clinical efficacy.
5, 55, 56 
2. Transdermal delivery-  
Ethosomes enhance permeability of drug through 
stratum corneum skin barrier, it can be use for 
administration of  those drugs having poor skin 
permeation, low oral bioavability, first pass metabolism 
and suppress infection of transdermal root.
 5, 56, 57, 58
 
Table 2: Application of Ethosomes as a Drug Carrier- 
5 
Drugs Results 
Anti- viral agents 
(Zidovudine)
 59
 
(Lamivudine)
60
 
(Stavudine) 
61
 
Prolonged drug action, reduced drug toxicity. 
Control release for prolonged period of time. 
Improved biological anti-inflammatory activity, sustained effect 
NSAIDS
62,63
 
(Diclofenac) 
(Aceclofenac) 
Selective and prolong delivery of drug to desired site. 
Superior to the marketed gel for the topical administration. 
 
Acyclovir
64
 Increased skin permeation and biological activity two to three times. 
Topical
65
 
Photodynamic Therapy (PDT) 
(5- aminolevulinic acid) 
Greater penetration ability than that of liposomes, More entrapment efficiency 
 
Insulin
66,67
 Significant decrease in blood glucose level. 
Trihexyphenidyl Hydrochloride
67
 Higher entrapment capacity, improved tansdermal flux, improved patient 
compliance. 
Antibiotic
68
 
(Erythromycin) (Cannabidol) 
Complete inhibition of infection, prolonged drug action. 
Improved skin deposition and biological activity. 
Pilosebaceous
69
 
(Minoxidil) 
High penetration into deep layers of the skin. 
Targeting 
Ammonium
70
 
Glycrrhizinate 
Improved biological anti-inflammatory activity, sustained effect. 
 
Salbutamol sulfate
71
 Controlled release rate, enhanced skin permeation. 
Testosterone
72
 Significantly higher permeation into the skin increased systemically delivery 
Propranolol
73
 Better skin permeation. 
Finasteride 
74
 Enhanced percutaneous absorption. 
Bacitracin
75
 Reduced drug toxicity. 
Methotrexate
76 
(MTX) 
Enhanced trans dermal flux, lower lag time, higher entrapment efficiency and 
better stability profile 
Gold Nanopartical
77
 Gold nanopartical in ethosomes shows enhancement of pharmacological efficacy 
in trans dermal and dermal delivery systems. 
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3. Delivery of HIV drugs- 
The antiretroviral therapy is a prolong therapy and has 
strong side effects.
5, 78
 The zero order delivery of 
zidovudine, Lamivudine is a potent antiviral agent and it 
required to maintain anti – AIDS effect. Ethosomal 
formulations of the above drugs prolong the release with 
increased transdermal influx
.5, 70
 The topical preparation 
of acyclovir is used as antiviral drug for treatment of 
herpes labials. It shows low therapeutic efficiency due to 
poor permeation through skin as replication of virus take 
places at the basal dermis. Ethosomal formulation of 
acyclovir show high therapeutic efficiency with shorter 
healing time and higher percentage of abortive lesions. 
  4. Delivery of problematic drug molecules- 
Oral delivery of large biogenic molecules such as 
peptides or proteins and insulin is difficult because they 
are completely degraded in the GIT tract hence 
transdermal delivery is a better dosage form. But 
conventional transdermal formulation of biogenic 
molecules such as peptides or protein and insulin has 
poor permeation. Formulating these biogenic molecules 
into ethosomal preparation increase permeation and 
therapeutic efficacy.
 5, 79  
 
5. Future Prospects- 
Introduction of ethosomes has started a new area in 
vesicular research for transdermal drug delivery. 
Different reports show a promising future of ethosomes 
in making transdermal delivery of various agents more 
effective. Further, research in this area will allow better 
control over drug release in vivo, allowing physician to 
make the therapy more effective. Ethosomes offers a 
good opportunity for the non-invasive delivery of small, 
medium and large sized drug molecules. The results of 
the first clinical study of acyclovir-ethosomal 
formulation support this conclusion. Multiliter quantities 
of ethosomal formulation can be prepared very easily. it 
can be a logical conclusion that ethosomal formulations 
possess promising future in effective dermal/transdermal 
delivery of bioactive agents. 
PATENTED AND MARKETED FORMULATION 
OF ETHOSOME- 
Ethosomes was invented and patented by Prof. Elka 
Touitou along with her students of department of 
Pharmaceutics at the Hebrew University School of 
Pharmacy. Novel Therapeutic Technologies Inc (NTT) 
of Hebrew University has been succeeded in bringing a 
number of products to the market based on Ethosomal 
delivery system. Noicellex TM an anti cellulite 
formulation of Ethosome is currently marketed in Japan. 
Lipoduction TM another formulation is currently used in 
treatment of cellulite containing pure grape seed extracts 
(antioxidant) is marketed in USA. Similarly Physonics 
is marketing anti cellulite gel Skin Genuity in London. 
Nanominoxc containing monoxidil is used as hair tonic 
to promote hair growth is marketed by Sinere.
 5, 62, 63 
 
Table 3: Marketed products based on Ethosomal drug delivery system- 
Name of product Uses Uses Manufacturer 
Celltight EF Topical cellulite cream, contains a powerful combination of 
ingredients to increase metabolism and break down fat 
Hampden Health,USA 
 
Decorin cream 
 
Anti-aging cream, treating, repairing, and delaying the visible 
aging signs of the skin including wrinkle lines, sagging, age 
spots, loss of elasticity, and hyper pigmentation 
Genome 
Cosmetics, 
Pennsylvania, 
US 
Nanominox 
 
First monoxidil containing product, which uses Ethosomes. 
Contains 4% Monoxidil, well-known hair growth promoter that 
must be metabolized by sulfation to the active compound 
Sinere, 
Germany 
Noicellex Topical anti-cellulite cream 
 
Novel Therapeutic 
Technologies, Israel 
Skin genuity Powerful cellulite buster, reduces orange peel Powerful cellulite buster, 
reduces orange peel 
 
CONCLUSION 
Ethosomes have been found to be much more efficient 
at delivering drug to the skin, it can be easily concluded 
that ethosomes can provide better skin permeation than 
liposomes. Ethosomes have been tested to encapsulate 
hydrophilic drugs, cationic drugs, proteins and peptides. 
Ethosomal carrier opens new challenges and 
opportunities for the development of novel improved 
therapies. Ethosomes are interesting and innovative 
vesicular systems that have appeared in the field of 
pharmaceutical technology and drug delivery in recent 
years. This carrier presents interesting features 
correlated with its ability to permeate intact through the 
human skin due to its high deformability. 
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